Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia

• Published in: International journal of hematology 2023-04, Vol.117 (4), p.530-537
• Main Authors: Zhang, Xian, Wu, Shulan, Yang, Junfang, Zhang, Gailing, Su, Yunchao, Zhang, Min, He, Jiujiang, Shi, Yanze, Li, Wenqian, Lu, Peihua, Lu, Daopei
• Format: Article
• Language: English
• Subjects: Acute promyeloid leukemia; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Arsenic; Arsenic - therapeutic use; Arsenic trioxide; Arsenic Trioxide - therapeutic use; Arsenicals - adverse effects; Chemotherapy; Hematology; Humans; Leukemia; Leukemia, Promyelocytic, Acute - therapy; Medicine; Medicine & Public Health; Mitoxantrone; Oncology; Original Article; Oxides - adverse effects; Promyeloid leukemia; Remission; Retinoic acid; Retrospective Studies; Side effects; Survival; Treatment Outcome; Tretinoin - therapeutic use
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-022-03507-5

Chemotherapy, all-trans retinoic acid (ATRA), and arsenic are effective options for acute promyelocytic leukemia (APL). We conducted a 20-year retrospective analysis of newly diagnosed (ND) APL patients treated with arsenic, ATRA and mitoxantrone. After achieving complete remission (CR), patients received 3–5 cycles of chemotherapy followed by AS4S4 maintenance for 3 years. Eighty-eight ND APL patients were treated with either oral AS4S4 ( n  = 42) or arsenic trioxide (ATO) ( n  = 46). The 8-year overall survival (OS) rate was 100% in the AS4S4 group and 90% in the ATO group. The disease-free survival (DFS) rates were 100% and 87.1% ( p  = 0.027), respectively. Patients in the ATO group had more side effects. A subsequent cohort of 33 ND APL patients received triple therapy with oral AS4S4, ATRA, and chemotherapy. The 13-year OS and DFS rates were 100% and 90.9%. Our long-term analyses show that APL patients with oral AS4S4 had better outcomes compared to ATO, with no need for hospitalization.